Who Exports Propranolol from India — 196 Suppliers Behind a $58.1M Market
India's propranolol export market is supplied by 196 active exporters who collectively shipped $58.1M across 3,988 shipments. IPCA LABORATORIES LIMITED leads with a 45.1% market share, followed by PAR FORMULATIONS PRIVATE LIMITED and AUROBINDO PHARMA LTD. The top 5 suppliers together control 86.5% of total export value, reflecting a concentrated market structure.
Top Propranolol Exporters from India — Ranked by Export Value
IPCA LABORATORIES LIMITED is the leading propranolol exporter from India, holding a 45.1% share of the $58.1M market across 3,988 shipments from 196 exporters. The top 5 suppliers — IPCA LABORATORIES LIMITED, PAR FORMULATIONS PRIVATE LIMITED, AUROBINDO PHARMA LTD, INTAS PHARMACEUTICALS LIMITED, AMNEAL PHARMACEUTICALS COMPANY (I) PRIVATE LIMITED — collectively control 86.5% of total export value, indicating a highly concentrated market. Individual shares are: IPCA LABORATORIES LIMITED (45.1%), PAR FORMULATIONS PRIVATE LIMITED (31.0%), AUROBINDO PHARMA LTD (4.9%), INTAS PHARMACEUTICALS LIMITED (3.5%), AMNEAL PHARMACEUTICALS COMPANY (I) PRIVATE LIMITED (2.0%).
Top Propranolol Exporters from India
Ranked by export value · 196 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | IPCA LABORATORIES LIMITED PROPRANOLOL HCL 20MG TAB 100 - PO NO. -HARMLESS MEDICINES APO-PROPRANOLOL 10MG TABLETSAPO-PROPRANOLOL 40MG TABLETS | $26.2M | 3 | 45.1% |
| 2 | PAR FORMULATIONS PRIVATE LIMITED PROPRANOLOL HCL 20MG TAB 100 - PO NO. -PROPRANOLOL HYDROCHLORIDETABLETSPROPRANOLOL HYDROCHLORIDETABLETS, | $18.0M | 1 | 31.0% |
| 3 | AUROBINDO PHARMA LTD PROPRANOLOL TABLETS 40MG(PROPRANOLOL 40PROPRANOLOL TABLETS 40MG(PROPRANOLOL ARRPHARMA DRUGS & MEDI PROPRANOLOL 10MG 5X1 | $2.9M | 5 | 4.9% |
| 4 | INTAS PHARMACEUTICALS LIMITED PHARMA DRUGS & MEDI PROPRANOLOL 10MG 5X1PHARMA DRUGS & MEDI PROPRANOLOL 40MG 5X1PHARMA DRUGS & MEDI PROPRANOLOL 40MG 25X | $2.1M | 5 | 3.5% |
| 5 | AMNEAL PHARMACEUTICALS COMPANY (I) PRIVATE LIMITED PROPRANOLOL HCL 20MG TAB 100 - PO NO. -PROPRANOLOL HYDROCHLORIDETABLETSPROPRANOLOL HYDROCHLORIDETABLETS, | $1.1M | 1 | 2.0% |
| 6 | AMNEAL PHARMACEUTICALS PRIVATE LIMITED PROPRANOLOL HCL 20MG TAB 100 - PO NO. -PROPRANOLOL HYDROCHLORIDETABLETSPROPRANOLOL HYDROCHLORIDETABLETS, | $1.1M | 1 | 1.9% |
| 7 | WATSON PHARMA PRIVATE LIMITED PROPRANOLOL HCL 20MG TAB 100 - PO NO. -PROPRANOLOL HYDROCHLORIDETABLETSPROPRANOLOL HYDROCHLORIDETABLETS, | $837.6K | 1 | 1.4% |
| 8 | AUROBINDO PHARMA LIMITED PROPRANOLOL TABLETS 40MG(PROPRANOLOL 40PROPRANOLOL TABLETS 40MG(PROPRANOLOL ARRPHARMA DRUGS & MEDI PROPRANOLOL 10MG 5X1 | $833.6K | 4 | 1.4% |
| 9 | MARKSANS PHARMA LIMITED PROPRANOLOL TABLETS 40MG(PROPRANOLOL 40PROPRANOLOL 40 MG TABLETS 140449X2 X14PKSPHARMACEUTICAL PRODUCTS - PROPRANOLOL 10MG TABLETS BP | $683.4K | 1 | 1.2% |
| 10 | FOURRTS (INDIA) LABORATORIES PRIVATE LIMITED PROPRANOLOL TABLETS 40MG(PROPRANOLOL 40PROPRANOLOL 40 MG TABLETS 140449X2 X14PKSPHARMACEUTICAL PRODUCTS - PROPRANOLOL 10MG TABLETS BP | $247.7K | 1 | 0.4% |
| 11 | KAUSIKH THERAPEUTICS PRIVATE LIMITED | $210.4K | 6 | 0.4% |
| 12 | FOURRTS INDIA LABORATORIES PRIVATE LIMITED PROPRANOLOL TABLETS 40MG(PROPRANOLOL 40PROPRANOLOL 40 MG TABLETS 140449X2 X14PKSPHARMACEUTICAL PRODUCTS - PROPRANOLOL 10MG TABLETS BP | $187.9K | 1 | 0.3% |
| 13 | INTAS PHARMACEUTICALS LTD PHARMA DRUGS & MEDI PROPRANOLOL 10MG 5X1PHARMA DRUGS & MEDI PROPRANOLOL 40MG 5X1PHARMA DRUGS & MEDI PROPRANOLOL 40MG 25X | $152.9K | 4 | 0.3% |
| 14 | CAPLIN POINT LABORATORIES LIMITED | $112.4K | 4 | 0.2% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Propranolol exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Intas Pharmaceuticals Limited | Warning Letter, July 2023 | Unknown | Unknown | Not verified | FDA issued a warning letter citing significant CGMP violations at the Sanand fac |
| Aurobindo Pharma Limited | Warning Letter, June 2019 | Unknown | Unknown | Not verified | FDA issued a warning letter for CGMP deviations at the Pydibhimavaram facility. |
| Amneal Pharmaceuticals Private Limited | Approved | Unknown | Unknown | 89 | FDA approved 89 ANDAs; no warning letters issued. |
| Ipca Laboratories Limited | Approved | Unknown | Unknown | Not verified | FDA approved; no warning letters issued. |
| Intas Pharmaceuticals Limited | Warning Letter, November | Unknown | Unknown | Not verified | FDA issued a warning letter citing CGMP violations at the Matoda-Sanand facility |
TransData Nexus reviewed the regulatory standing of 5 leading Propranolol exporters from India. 2 hold US FDA facility approvals, 0 maintain WHO-GMP certification, and 0 are EU GMP compliant. 3 suppliers have received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Propranolol sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is renowned for its production of active pharmaceutical ingredients (APIs). The city hosts numerous API manufacturers, including major players like Aurobindo Pharma Ltd. Aurobindo Pharma Ltd. has contributed significantly to Propranolol exports, accounting for $2.9 million, or 4.9% of total exports. The presence of such companies underscores Hyderabad's pivotal role in the API segment of the pharmaceutical industry.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is a prominent hub for pharmaceutical formulations. Companies in this region focus on producing finished dosage forms, including tablets and capsules. Notably, Intas Pharmaceuticals Limited, based in Ahmedabad, has been a key exporter of Propranolol, contributing $2.1 million, or 3.5% of total exports. This highlights the region's strength in formulation development and manufacturing.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a crucial export gateway for pharmaceutical products. The region's well-developed port infrastructure facilitates efficient international shipping. Companies like Ipca Laboratories Limited, headquartered in Mumbai, have leveraged this advantage, becoming the leading exporter of Propranolol with exports totaling $26.2 million, representing 45.1% of total exports. This underscores the region's strategic importance in the export supply chain.
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh has attracted numerous pharmaceutical companies due to favorable tax incentives. This area has become a manufacturing hub, particularly for companies seeking cost advantages. While specific export data for Propranolol from this region is not detailed, the presence of manufacturing facilities contributes to the overall production capacity and export potential of the country.
5Sourcing Recommendations
- Diversify Supplier Base: While Ipca Laboratories Limited is the dominant exporter, accounting for 45.1% of Propranolol exports, it's prudent to engage with multiple suppliers to mitigate risks associated with over-reliance on a single source.
- Evaluate Regional Strengths: Consider sourcing APIs from Hyderabad-based manufacturers like Aurobindo Pharma Ltd. and formulations from companies in the Ahmedabad-Vadodara corridor, such as Intas Pharmaceuticals Limited, to leverage regional expertise.
- Leverage Export Infrastructure: Utilize the robust export facilities in the Mumbai-Thane-Raigad region to ensure efficient and timely international shipments.
- Monitor Regulatory Compliance: Ensure that all suppliers comply with international regulatory standards, including those set by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), to maintain product quality and market access.
By strategically engaging with suppliers across these key pharmaceutical clusters, companies can optimize their Propranolol sourcing strategies, ensuring a stable and efficient supply chain.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Propranolol exporters from India
Amneal Pharmaceuticals — Amneal invests $200M in new Ahmedabad facilities
Amneal Pharmaceuticals announced a $200 million investment to develop two new manufacturing facilities in Ahmedabad, India, aimed at producing weight loss drugs. - IMPACT: This expansion may enhance Amneal's production capabilities, potentially increasing Propranolol exports.
Impact: This expansion may enhance Amneal's production capabilities, potentially increasing Propranolol exports.
Amneal Pharmaceuticals — Amneal receives first product approval in China
Amneal Pharmaceuticals received approval to launch its first product, Sevelamer carbonate, in China, marking its entry into the Chinese market. - IMPACT: Entry into the Chinese market could diversify Amneal's revenue streams, potentially affecting its focus on Propranolol exports.
Impact: Entry into the Chinese market could diversify Amneal's revenue streams, potentially affecting its focus on Propranolol exports.
Amneal Pharmaceuticals — Amneal acquires Punishka Healthcare
Amneal Pharmaceuticals acquired Punishka Healthcare, expanding its capacity to manufacture injectable medicines at a 293,000 sq. foot facility near Ahmedabad, India. - IMPACT: The acquisition may bolster Amneal's production capabilities, potentially increasing Propranolol exports.
Impact: The acquisition may bolster Amneal's production capabilities, potentially increasing Propranolol exports.
Common Questions — Propranolol Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which propranolol supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, IPCA LABORATORIES LIMITED leads with 55 recorded shipments worth $26.2M. PAR FORMULATIONS PRIVATE LIMITED (109 shipments) and AUROBINDO PHARMA LTD (103 shipments) are also established high-volume exporters.
Q How many propranolol manufacturers are there in India?
India has 196 active propranolol exporters with a combined export market of $58.1M across 3,988 shipments to 99 countries. The top 5 suppliers hold 86.5% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for propranolol from India?
Average FOB unit price: $5.49 per unit, ranging from $0.00 to $8786.37. Average shipment value: $14.6K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 196 verified Indian exporters of Propranolol ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 3,988 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 99 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
3,988 Verified Shipments
196 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists